Yet again you respond to one inquiry. Like formerly mentioned; patents are superb to have in a portfolio, but 2 patents with countless rejections, and 31 pending patents is not something to boast, that is truly upsetting. Perhaps focus on real success than what appears to be trial and error?
There is not one Wall Street analyst that values a development-stage biotech company primarily or even secondarily through the prism of patents. Not one.
Do Wall Street analysts value biotech companies that have FDA-approved products on the market and active revenue streams through a prism (but not the only one) of patents? Yes, they do. But a development-stage zombie biotech company that has zero revenues, zero approved drugs, zero ongoing clinical trials, and is insolvent? HELL NO!
That Venturis Therapeutics's supporters feel the need to grossly misrepresent how things work shows one of two things: (1) they're idiots; or (2) they think everyone else is stupid.
But let's not forget that ZOMBIE COMPANIES only talk about things that are irrelevant. What zombie companies don't do is talk about the only thing that matters for a development-stage biotech company: running clinical trials.
News 
Market Data 
Discover 
